2024-12-27  5:25:24 PM Chg. +1.24 Volume Bid8:59:53 PM Ask8:59:53 PM Market Capitalization Dividend Y. P/E Ratio
93.09EUR +1.35% 0
Turnover: 0.00
-Bid Size: - -Ask Size: - 116.94 bill.EUR 4.03% 21.64

Business description

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
 

Management board & Supervisory board

CEO
Paul Hudson
Management board
François-Xavier Roger, Houman Ashrafian, Natalie Bickford, Olivier Charmeil, Brian Foard, Emmanuel Frenehard, Brendan O’Callaghan, Roy Papatheodorou, Madeleine Roach, Thomas Triomphe, Julie Van Ongevalle
Supervisory board
Frédéric Oudéa, Paul Hudson, Christophe Babule, Clotilde Delbos, Rachel Duan, Carole Ferrand, Lise Kingo, Patrick Kron, Wolfgang Laux, Barbara Lavernos, Fabienne Lecorvaisier, Anne-Françoise Nesmes, Gilles Schnepp, John Sundy, Ceng-Yann Tran, Emile Voest, Antoine Yver
 

Company data

Name: Sanofi S.A.
Address: 54, Rue La Boétie,F-75008 Paris
Phone: +33-1-53-77-40-00
Fax: +33-1-53-77-43-03
E-mail: -
Internet: https://www.sanofi.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: 88.70%
IPO date: -

Investor relations

Name: Eva Schaefer-Jansen
IR phone: +33-1-53-77-45-45
IR Fax: -
IR e-mail: investor.relations@sanofi.com

Company calendar

CW 5 | 2025-01-30 4th Quarter/Annual Report
CW 17 | 2025-04-24 Interim Report 1st Quarter/3 Months
CW 31 | 2025-07-31 Interim Report 2nd Quarter/6 Months
CW 43 | 2025-10-24 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Non-French institutional
 
66.20%
French institutional
 
11.20%
L'Oréal S.A.
 
9.40%
Others
 
6.40%
Miscellaneous
 
3.60%
Employees
 
3.20%